The Sydney Myopia Study: Prevalence And Risk Factors For Myopia And Other Eye Conditions In School-age Children.
Funder
National Health and Medical Research Council
Funding Amount
$596,375.00
Summary
This study aims to establish the exact extent of increasing levels of myopia in young Australians and the frequency of other treatable eye conditions such as reduced vision in one eye (amblyopia) and squint. We also aim to exam in detail, risk factors associated with myopia, such as parental myopia, living conditions and educational pressures, particularly those associated with reading and other forms of near-work. Increased understanding of factors leading to increasing myopia prevalence may en ....This study aims to establish the exact extent of increasing levels of myopia in young Australians and the frequency of other treatable eye conditions such as reduced vision in one eye (amblyopia) and squint. We also aim to exam in detail, risk factors associated with myopia, such as parental myopia, living conditions and educational pressures, particularly those associated with reading and other forms of near-work. Increased understanding of factors leading to increasing myopia prevalence may enable design of preventive strategies that could limit future increases in the ocurrence of myopia in Australia. The prevalence of myopia is increasing world-wide. In many Asian countries, it has reached epidemic proportions (80-90%) in young, educated people. In many other countries close to half the younger population is now short-sighted. Data from the Blue Mountains Eye Study and Melbourne Visual Impairment Project in older persons have suggested that the prevalence of myopia is increasing in Australia. Comparison with our recent pilot study on school children indicates that myopia prevalence has increased 2 to 3-fold in recent decades. Myopia or short-sightedness is now one of the five major causes of blindness. In countries where the prevalence of myopia is high, it is one of the top three. Myopia requires expensive optical and-or surgical correction of the refractive error for visual functioning. Unfortunately correction does not prevent the development of visual impairment and blindness from complications of myopia. Late in life, even low myopia is associated with an increased risk of both glaucoma and cataract. Myopia therefore imposes additional major health costs because of the burden of eye disease and the support costs for people affected by myopia-associated low vision or blindness. With increasing prevalence, the health care costs of myopia are likely to continue to rise in Australia.Read moreRead less
Characterising The Changes In Regulation Of Visual Contrast Sensitivity In Glaucoma.
Funder
National Health and Medical Research Council
Funding Amount
$337,600.00
Summary
Glaucoma is the second leading cause of blindness in developed nations. A recent study estimated the number of Australian's that will need regular visual examination in 2030 either because they have glaucoma or glaucomatous risk factors to be at least 800,000. As the ultimate aim of glaucoma treatment is to maintain vision, visual functional assessment is of paramount importance to glaucoma management . The current standard measure for the assessment of visual loss due to glaucoma is visual fiel ....Glaucoma is the second leading cause of blindness in developed nations. A recent study estimated the number of Australian's that will need regular visual examination in 2030 either because they have glaucoma or glaucomatous risk factors to be at least 800,000. As the ultimate aim of glaucoma treatment is to maintain vision, visual functional assessment is of paramount importance to glaucoma management . The current standard measure for the assessment of visual loss due to glaucoma is visual field testing. Regrettably, substantial damage to retinal ganglion cells (the primary neurons affected by glaucoma) is often present prior to the discovery of visual field loss using standard measures. Indeed studies have demonstrated that even 30-50% retinal ganglion cell loss may only manifest as a mild visual field deficit using current standard testing. This project will use novel techniques for exploring sight impairment in glaucoma, enabling a better understanding of the underlying neural damage. Our pilot work demonstrates that these methods can detect loss of sight in areas diagnosed as normal using standard visual field testing. The study will provide new technologies for the assessment of early vision loss due to glaucoma that may enable the detection of malfunction of retinal ganglion cells prior to their death. Such measures of neural malfunction are essential to establishing the efficacy of new pharmacological therapies (known as neuroprotective agents) for glaucoma aimed at keeping retinal ganglion cells alive and functioning. This project also has the potential to identify visual measures that have better capability for monitoring the progression of vision loss due to glaucoma. Early detection of glaucoma and its progression is essential so that treatment can be initiated or altered, slowing the progression of vision loss and its toll on both the individual and the community.Read moreRead less
Thalamic inputs and cortical microcircuitry underlying the functional architecture of the visual cortex. This project seeks to reveal the fundamental circuitry of the visual cortex that enables visual perception. Such understanding is essential not only for explaining many perceptual disturbances, but also for providing a neuronal basis for developing functionally useful prostheses for the blind.
Removing the blinkers: a wider study of the human eye. Peripheral aberrations, wide-field retinal imaging and optical parameters. This project will study peripheral (side vision) optics of the human eye and its role in the limits of visual performance. This will improve ocular measurements and contribute towards improved diagnosis and treatment of ocular diseases and short-sightedness.
Advanced methods for intraocular imaging. The ability to image the retina of the human eye at high resolution is fundamental to improving understanding of ocular physiology, ocular optics and disease diagnosis. This project applies the relatively new application of active optics to vision science. This project will investigate the advantages of using new beam shaping techniques for characterising the optics of the eye, improving retinal imagery and improving fixation stability. This project will ....Advanced methods for intraocular imaging. The ability to image the retina of the human eye at high resolution is fundamental to improving understanding of ocular physiology, ocular optics and disease diagnosis. This project applies the relatively new application of active optics to vision science. This project will investigate the advantages of using new beam shaping techniques for characterising the optics of the eye, improving retinal imagery and improving fixation stability. This project will achieve three-dimensional holography of human eyes and develop holography plates for correcting the aberrations of eyes. Expected outcomes are not-before experienced resolution images of the retina and better understanding of the optical characteristics of the refractive surfaces and media in the eye.Read moreRead less
Dynamic ocular imaging: New tools to study neurodegenerative disease. Neurovascular uncoupling occurs when blood supply and energy production is no longer responsive to the metabolic of nervous tissue. Neurovascular uncoupling is thought to be a key mechanism in the development of debilitating neurodegenerative diseases such as Alzheimer’s disease and glaucoma. This project will be the first study to develop, validate and employ a comprehensive suite to simultaneously image blood flow, oxygen sa ....Dynamic ocular imaging: New tools to study neurodegenerative disease. Neurovascular uncoupling occurs when blood supply and energy production is no longer responsive to the metabolic of nervous tissue. Neurovascular uncoupling is thought to be a key mechanism in the development of debilitating neurodegenerative diseases such as Alzheimer’s disease and glaucoma. This project will be the first study to develop, validate and employ a comprehensive suite to simultaneously image blood flow, oxygen saturation, metabolic activity and retinal function to understand neurovascular uncoupling in aging and age-related neurodegeneration. Read moreRead less
Histamine and non-visual regulation of retinal signalling. This project is internationally competitive, asking basic biological questions about the brain and vision. Of direct national benefit, the new knowledge generated may alter the way we understand how vision works. Ultimately this knowledge may give insight into particular health issues, such as the persistence of visual memory in Post Traumatic Stress Disorder, and age related diseases such as Alzheimer's disease. Further this new kno ....Histamine and non-visual regulation of retinal signalling. This project is internationally competitive, asking basic biological questions about the brain and vision. Of direct national benefit, the new knowledge generated may alter the way we understand how vision works. Ultimately this knowledge may give insight into particular health issues, such as the persistence of visual memory in Post Traumatic Stress Disorder, and age related diseases such as Alzheimer's disease. Further this new knowledge will flow directly into the reputation of our major institutes of higher education and strengthen their place on the world stage. Through both CIs, this research will contribute to the education of both undergraduate and postgraduate science students at The University of Melbourne. Read moreRead less
Using the eye as a window to the central nervous system for improved drug testing. The annual cost of treating brain illnesses is US$250 billion. Each new drug costs about US$900 million to develop. This research will give Pfizer Pty Ltd, the project’s industry partner, a more efficient and direct way of testing whether drugs can get into and affect the brain. This will reduce the cost of drug development, which ultimately means cheaper drugs. The project will develop new technologies to put Aus ....Using the eye as a window to the central nervous system for improved drug testing. The annual cost of treating brain illnesses is US$250 billion. Each new drug costs about US$900 million to develop. This research will give Pfizer Pty Ltd, the project’s industry partner, a more efficient and direct way of testing whether drugs can get into and affect the brain. This will reduce the cost of drug development, which ultimately means cheaper drugs. The project will develop new technologies to put Australia at the forefront of neuropharmaceutical and neuroscience research. A new research platform will foster collaborations with the pharmaceutical industry both within Australia and overseas. This industrial link will promote a unique post-graduate experience by providing exposure to academic and industrial environments for Australian scientists.Read moreRead less